Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: Negligible effects of increase in CYP3A1 on the metabolism of telithromycin

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 4, 2007, Pages 157-166

  Lee, Joo H ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

CYP3A1 2; Pharmacokinetics; Rats; Telithromycin; U ARF

Indexed keywords

CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE SODIUM PHOSPHATE; ISOENZYME; TELITHROMYCIN; TROLEANDOMYCIN; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; FIRST PASS EFFECT; KIDNEY CLEARANCE; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; HALF-LIFE; INFUSIONS, INTRAVENOUS; ISOENZYMES; KETOLIDES; KIDNEY FAILURE, ACUTE; MALE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34247569030     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.542     Document Type: Article

References (40)

1. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol 1998; 37: 418-425.
2. Yassin HM, Dever LL. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Investig Drugs 2001; 10: 353-367.
3. van Rensburg D, Fogarty C, De Salvo MC, Rangaraju M, Nusrat R. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. J Infect 2005; 51: 201-205.
4. Nguyen M, Chung EP, Telithromycin: the first ketolide antimicrobial. Clin Ther 2005; 27: 1144-1163.
5. Namour F, Wessels DH, Pascual MH, Reynolds D, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001; 45: 170-175.
6. Chung HC, Kim SH, Lee MG, Kim SG. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): the role of urea in CYP2E1 induction by acute renal failure. Drug Metab Dispos 2002; 30: 739-746.
7. Moon YJ, Lee AK, Chung HC, et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
8. Lee MG, Lee JH, Oh JM. Pharmacokinetic changes of drugs in uranyl nitrate-induced acute renal failure rats: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Curr Clin Pharmacol 2006; 1: 193-205.
9. Diaz A, Alvarez M, Callejas C, Rosso R, Schnettler K, Saldias F. Clinical picture and prognostic factors for severe community-acquired pneumonia in adults admitted to the intensive care unit. Arch Bronchopneumol 2005; 41: 20-26.
10. Itoh A, Tomioka H, Isobe M, et al. Successful telithromycin therapy of Legionella pneumonia - Report of three cases. Kansenshogaku Zasshi 2006; 80: 418-422.
11. Shi J, Montay G, Chapel S, et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol 2004; 44: 234-244.
12. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44: 915-934.
13. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
14. Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43: 90-95.
15. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
16. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-780.
17. Øie S, Guentert TW. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 1982; 71: 127-128.
18. Arlotto MP, Sonderfan AJ, Klaassen CD, Parkinson A. Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase. Biochem Pharmacol 1987; 36: 3859-3866.
19. Halpert JR. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Arch Biochem Biophys 1988; 263: 59-68.
20. Sinclair JF, Szakacs JG, Wood SG, et al. Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin. Biochem Pharmacol 2000; 59: 445-454.
21. Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B, Guzelian PS. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat livers as the glucocorticoid responsive cytochrome P-450p. Biochemistry 1985; 24: 2171-2178.
22. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
23. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel Dekker: New York, 1982.
24. Chiou WL. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 1980; 69: 90-91.
25. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
26. Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimens. J Pharm Sci 1979; 68: 1067-1069.
27. Bae SK, Lee SJ, Kim YH, Kim T, Lee MG. Effect of enzyme inducers and inhibitors on the pharmacokinetics of oltipraz in rats. J Pharm Pharmacol 2005; 57: 443-452.
28. Lee DY, Lee SJ, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. Int J Pharm 2005; 298: 38-46.
29. Lewis DFV. P450 substrate specificity and metabolism. In Cytochrome P450. Structure, Function and Mechanism, Lewis DFV (ed.). Taylor & Francis: Bristol, 1996; 123.
30. Kim SH, Shim HJ, Kim WB, Lee MG. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob Agents Chemother 1998; 42: 1217-1221.
31. Lee AK, Lee JH, Kwon JW, et al. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 2004; 25: 273-282.
32. Lee YH, Ku YS. Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol 1998; 102: 251-264.
33. Shim HJ, Kim YC, Kim EJ, et al. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 2004; 25: 137-142.
34. Son IJ, Moon YJ, Lee MG, Sohn YT. Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol 2000; 108: 359-368.
35. Fruncillo RJ, Swanson BN, Bernhard R, Marchion C, Ferguson RK. Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. J Pharm Sci 1986; 75: 150-154.
36. Matzke GR, Millikins SP. Influence of renal function and dialysis on the drug disposition. In Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring (3rd edn), Evans WE, Schentag JJ, Jusko WJ (eds). Applied Therapeutics: Vancouver, 1992; 8-8-8-10.
37. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
38. Kurtz TW, Maletz RM, Hsu CH. Renal cortical blood flow in glycerol-induced acute renal failure in the rat. Circ Res 1976; 38: 30-35.
39. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
40. Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2002; 13: 1579-1585.